Viral kinetics in hepatitis C virus: Special patient populations

Seminars in Liver Disease

Volumn 23, Issue SUPPL. 1, 2003, Pages 29-33

  Layden Almer, Jennifer E ^a   Layden, Thomas J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

African Americans; Chronic hepatitis C virus infection; Genotype 1; HIV HCV co infection; Mathematical modeling; Obesity; Peginterferon; Ribavirin; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETRON; RIBAVIRIN; VIRUS RNA;

ANTIBIOTIC RESISTANCE; CAUCASIAN; CHRONIC HEPATITIS; COMORBIDITY; CONFERENCE PAPER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RATE; MATHEMATICAL MODEL; MICROBIAL KINETICS; NEGRO; OBESITY; OPTIMAL DRUG DOSE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SUSTAINED VIROLOGICAL RESPONSE; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; DRUG CARRIERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; OBESITY; POLYETHYLENE GLYCOLS; RNA, VIRAL;

EID: 0041317672     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989:321:1501-1506
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
3. Zeuzem S, Feinman V, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic Hepatitis C. N Engl J Med 2000;343:1666-1672
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b in combination with ribavirin compared with interferion alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001:358:958-965
5. Heathcote J, Shiffman M, Cooksley G, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680
6. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in response to therapy with IFN in chronic hepatitis C. Hepatology 1999;30:787-793
7. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-1323
8. Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with gentoype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepatitis 2001;8:264-269
9. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126
10. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996;271:1582-1586
11. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human deficiency virus type 1 infection. Nature 1995;373:117-122
12. Nowak MA, Bonhoeffer S, Hill A, et al. Viral dynamics in hepatitis B infection. Proc Natl Acad Sci U S A 1996;93:4398-4402
13. Zeuzem S, de Man RA, Honkoop P, et al. Dynamics of hepatitis B virus infection in vivo. J Hepatology 1997;27:431-436
14. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869
15. Lewin SR, Ribeiro RM, Walters T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1020
16. Zeuzem S, Schmidt JM, Lee JH, et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-371
17. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with Interferon alfa. Hepatology 1997;26:226-231
18. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of IFN-α therapy. Science 1998;282:103-107
19. Zhu H, Nelson D, Crawford J, Liu C. Interferon alpha induced antiviral activity in Hepatitis C viral replicon cell cultures. Hepatology 2001;34:347A (Abst)
20. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary IFN resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001;358:1241-1242
21. Layden TJ, Layden JE, Reddy KR, et al. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepatitis 2002;9:334-339
22. Layden JE, Layden TJ, Reddy KR, et al. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepatitis 2002;9:340-345
23. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 hepatitis C virus. J Infect Dis 2000;182:28-35
24. Lam NP, DeGuzman LJ, Pitrak D, Layden TJ. Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection. Dig Dis Sci 1994;39:2660-2664
25. Davis GL, Lindsay K, Albrecht J, et al. Clinical predictors of response to recombinant interferon- alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. J Viral Hepat 1994;1:55-63
26. Pawlotsky JM, Roudot-Thoraval F, Bastie A, et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis 1996;174:1-7
27. Lam NP, Pitrak D, Speralakis R, et al. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997;42:178-185
28. Neumann AU, Reddy R, Levy-Drummer R, et al. IFN pharmacokinetics and host factors: effects on hepatitis C genotype 1 viral kinetics during treatment with CIFN. Hepatology 2000;32:4
29. Layden JE, Reddy KR, Kozlowski M, et al. Differences in viral kinetic parameters in response to IFN treatment between African Americans and Caucasians infected with genotype 1 virus. Hepatology 2001;34 (Abst)
30. Layden-Almer JE, Ribeiro RM, Wiley TE, et al. Viral dynamics and response differences in HCV infected African Americans and Caucasians treated with IFN and ribavirin. Hepatology 2003;37:1343-1350